In addition to CG001419, Cullgen continues the advancement of CG009301, a GSPT1 degrader being studied in a Phase 1 trial for the treatment of blood cancers, as well as progressing its pipeline of pre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback